Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection

NCT01624571 is registered in ClinicalTrials.gov with LG Life Sciences as lead sponsor.

NCT NCT01624571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01624571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection
Lead sponsor
LG Life Sciences
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
October 31, 2012
Enrollment
147 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

_large interstinal surgery, colon resection